On November 18, 2024, Advance Tests announced the exclusive UK launch of LucentAD Complete, an innovative multi-marker blood test for Alzheimer's Disease. This test was developed by Lucent Diagnostics, a commercial brand of Quanterix Corporation.
The LucentAD Complete test provides highly accurate risk classification for amyloid pathology associated with Alzheimer's Disease, achieving 90% accuracy. It combines several Alzheimer's-related biomarkers, including p-Tau 217, Aβ42/40, GFAP, and NfL.
Bookings for the test became available on November 18, 2024, for appointments starting December 2, 2024, priced at £695. Patient samples will be analyzed in Lucent laboratories in the USA, with results available within 15 working days, marking a significant step in accessible Alzheimer's diagnostics in the UK.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.